Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw

Journal of Clinical Oncology

Volumn 27, Issue 32, 2009, Pages 5356-5362

  Vahtsevanos, Konstantinos ^a   Kyrgidis, Athanassios ^a   Verrou, Evgenia ^a   Katodritou, Eirini ^a   Triaridis, Stefanos ^a   Andreadis, Charalampos G ^a   Boukovinas, Ioannis ^a   Koloutsos, Georgios E ^a   Teleioudis, Zisis ^a   Kitikidou, Kyriaki ^a   Paraskevopoulos, Panagiotis ^a   Zervas, Konstantinos ^a   Antoniades, Konstantinos ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DENTURE; DISEASE COURSE; DRUG SAFETY; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; JAW OSTEONECROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PERIODONTITIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; RISK REDUCTION; SEX RATIO; SINGLE DRUG DOSE; SMOKING; TOOTH EXTRACTION; TOOTH ROOT CANAL; TREATMENT OUTCOME; BONE NECROSIS; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; GREECE; JAW DISEASE; KAPLAN MEIER METHOD; MIDDLE AGED; PROSTATE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; GREECE; HUMANS; IMIDAZOLES; INCIDENCE; JAW DISEASES; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 73849148160     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.9584     Document Type: Article

References (29)

1. Kyrgidis A, Vahtsevanos K, Koloutsos G, et al: Biphosphonate related osteonecrosis of the jaws: Risk factors in breast cancer patients - A case control study. J Clin Oncol 26:4634-4638, 2008
2. Coleman RE: Risks and benefits of bisphosphonates. Br J Cancer 98:1736-1740, 2008
3. American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369-376, 2007
4. Edwards BJ, Gounder M, McKoy JM, et al: Pharmacovigilance and reporting oversight in US FDA fast-track process: Bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166-1172, 2008
5. Marx RE: Bisphosphonate-induced osteonecrosis of the jaws: A challenge, a responsibility, and an opportunity. Int J Periodontics Restorative Dent 28:5-6, 2008
6. Sarin J, DeRossi SS, Akintoye SO: Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14:277-285, 2008
7. Raje N, Woo SB, Hande K, et al: Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 14:2387-2395, 2008
8. Gómez Font R, Martinez Garcia ML, Olmos Martinez JM: Osteochemonecrosis of the jaws due to bisphosphonate treatments: Update. Med Oral Patol Oral Cir Bucal 13:E318-E324, 2008
9. Walter C, Al-Nawas B, Grotz KA, et al: Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066-1072, 2008
10. Kyrgidis A, Andreadis C: Clinical characterization might help in preventing osteonecrosis of the jaw. Clin Cancer Res 14:8321, 2008
11. Hess LM, Jeter JM, Benham-Hutchins M, et al: Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121:475-483 e3, 2008
12. Skaleric U, Kovac-Kavcic M: Some risk factors for the progression of periodontal disease. J Int Acad Periodontol 2:19-23, 2000
13. Magopoulos C, Karakinaris G, Telioudis Z, et al: Osteonecrosis of the jaws due to bisphosphonate use: A review of 60 cases and treatment proposals. Am J Otolaryngol 28:158-163, 2007
14. García-Closas M, Lubin JH: Power and sample size calculations in case-control studies of gene-environmental interactions: Comments on different approaches. Am J Epidemiol 149:689-692, 1999
15. Stumpe MR, Chandra RK, Yunus F, et al: Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck 31:202-206, 2009
16. Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23:8580-8587, 2005
17. Zervas K, Verrou E, Teleioudis Z, et al: Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 134:620-623, 2006
18. Wang EP, Kaban LB, Strewler GJ, et al: Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65:1328-1331, 2007
19. Estilo CL, Van Poznak CH, Wiliams T, et al: Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13:911-920, 2008
20. Hoff AO, Toth BB, Altundag K, et al: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826-836, 2008
21. Landesberg R, Cozin M, Cremers S, et al: Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839-847, 2008
22. Kyrgidis A, Vahtsevanos K: Increased risk for bisphosphonate related osteonecrosis of the jaws in patients wearing overdentures could be attributable to impaired mucosal cell wound healing. J Oral Maxillofac Surg 67:1355-1356, 2009
23. Triaridis S, Vahtsevanos K: New evidence on bisphosphonate related osteonecrosis of the jaws suggests dental referral prior to commencement of treatment. Hippokratia 13:64, 2009
24. Badros A, Terpos E, Katodritou E, et al: Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 26:5904-5909, 2008
25. US National Institutes of Health, ClinicalTrials.gov: Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer. http://www.clinicaltrials.gov/ ct2/show/record/NCT00127205
26. US National Institutes of Health, ClinicalTrials.gov: Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer. http://www.clinicaltrials.gov/ct2/show/record/NCT00326820
27. US National Institutes of Health, ClinicalTrials.gov: A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain. http://www.clinicaltrials.gov/ct2/show/record/NCT00099177
28. US National Institutes of Health, ClinicalTrials.gov: A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease. http://www.clinicaltrials.gov/ct2/show/record/ NCT00099203
29. Kyrgidis A, Andreadis C: Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonates osteonecrosis of the jaw in breast cancer patient. Oncologist 14:101-102, 2009